DYNE THERAPEUTICS DL-0001

At the Cantor conference, Dyne Therapeutics announced plans to commercialize two lead programs: Z-Rostudirsen (PDUFA Jan. 21) for Duchenne muscular dystrophy and Z-Basivarsen for myotonic dystrophy type 1. The FORCE platform is intended to enable deep tissue and CNS distribution and serves as a differentiator. Pro-forma cash of $1.3 billion secures operations through the second quarter of 2028 and supports building commercial, manufacturing and further development capabilities. Dyne is pursuing a two-pronged approval strategy for DM1 while simultaneously expanding its DMD exon-skipping programs. » Mais em de.investing.com

Dyne Therapeutics' stock plunged 31.0% to $16.76 in pre-market trading, with no official company statement yet explaining the reason. The sharp drop points to a company-specific negative event in the regulatory, clinical, or product-pipeline area. Relevant upcoming events include a PDUFA decision for z-rostudirsen (DYNE-251) on January 21, 2027, and topline data for the expansion cohort of z-basivarsen in Q1 2027. Dyne also reported a larger quarterly loss of about $178.6 million (loss/share -$1.08) versus consensus -$0.75, while the broader market showed no comparable move. » Mais em de.investing.com

Dyne Therapeutics will present preclinical data for four investigational therapies (DYNE-253, DYNE-245, DYNE-244, DYNE-255) for Duchenne muscular dystrophy at the 27th annual meeting of the Neuromuscular Study Group. The candidates target exon-skipping for exons 53, 45, 44, and 55, respectively. All four are in studies relevant to IND-enabling submissions, and the presentation includes in vitro exon-skipping data; DYNE-253 data also include in vivo pharmacokinetic and pharmacodynamic results, including dystrophin levels in the Del52 mouse model. The therapies are based on the FORCE platform, which is also used for DYNE-251 (zeleciment rostudirsen), whose approval for exon-51 mutations is currently under FDA review. The poster session takes place on September 25 and the presentation will be available on Dyne’s website at the start of the session. » Mais em de.investing.com